Amondys 45 (casimersen) and Vyondys 53 (golodirsen)
Sarepta Therapeutics (SRPT)
Decision dateFeb 28, 2027
105 days away
Marketer take
The confirmatory trial missed its primary endpoint and the company says FDA action could change labels, so DMD marketers should track this closely.
- Sponsor company
- Sarepta Therapeutics (SRPT)
- Indication
- Duchenne muscular dystrophy, sNDAs after confirmatory ESSENCE trial
- Therapeutic area
- Neurology, Rare disease
- Event
- PDUFA target action date
- Date
- Feb 28, 2027
- Status
- Upcoming
- Source
- SEC filing
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?